Oyando R, Njoroge M, Nguhiu P, et al. Patient costs of diabetes mellitus care in public health care facilities in Kenya. Int J Health Plann Mgmt. 2020;35:290--308. 10.1002/hpm.2905

1. BACKGROUND {#hpm2905-sec-0005}
=============

Diabetes mellitus (DM) is a chronic, incurable, and potentially disabling disease that presents a substantial public health challenge worldwide.[1](#hpm2905-bib-0001){ref-type="ref"} Evidence suggests that the unprecedented increase in DM burden has major clinical, economic, and social implications particularly in low‐ and middle‐income countries (LMICs).[2](#hpm2905-bib-0002){ref-type="ref"}, [3](#hpm2905-bib-0003){ref-type="ref"}, [4](#hpm2905-bib-0004){ref-type="ref"}, [5](#hpm2905-bib-0005){ref-type="ref"}, [6](#hpm2905-bib-0006){ref-type="ref"}, [7](#hpm2905-bib-0007){ref-type="ref"} In addition to reducing well‐being, the chronic nature and complications associated with DM may lead to substantial costs of medical care and productivity losses to patients and their households. Unfortunately, progress in attainment of Sustainable Development Goal 3.4 that aims to reduce premature mortality from noncommunicable diseases (NCDs) by one‐third by 2030 continues to be constrained by, inter alia, weak health systems in most LMICs.[1](#hpm2905-bib-0001){ref-type="ref"}

The Kenyan health system is devolved, with the National Ministry of Health (MOH) having policy and regulatory roles while the 47 county health systems have service provision roles.[8](#hpm2905-bib-0008){ref-type="ref"} Service delivery is pluralistic and is characterized by a mix of public, private for‐profit, and private not‐for‐profit providers.[9](#hpm2905-bib-0009){ref-type="ref"}, [10](#hpm2905-bib-0010){ref-type="ref"} Kenya\'s public health care delivery system is organized into six levels. Level 1 is composed of community health services that include all community‐based demand creation activities that are guided by the MOH community strategy. Levels 2 and 3 refer to dispensaries and health centers, respectively, which offer outpatient primary health care services. Level 4 represents subcounty hospitals that are first referral hospitals while level 5 represents county referral hospitals that provide secondary care. Level 6 represents national tertiary referral hospitals. Diabetes care is typically offered through dedicated specialized clinics located in public levels 4 to 6 hospitals.[11](#hpm2905-bib-0011){ref-type="ref"}, [12](#hpm2905-bib-0012){ref-type="ref"}, [13](#hpm2905-bib-0013){ref-type="ref"}, [14](#hpm2905-bib-0014){ref-type="ref"} In some areas, however, patients can access medication from health centres and dispensaries, but this is the exception rather than the norm. Each of these levels are expected to provide some aspects of preventive, promotive, curative, and rehabilitative services as outlined in the Kenya Essential Package for Health,[15](#hpm2905-bib-0015){ref-type="ref"} which includes interventions and services targeted at DM. Private providers mimic this classification though most are stand‐alone units with weak referral mechanisms. Kenya\'s health system is financed by (a) tax revenues collected by the government (national and county), (b) donor funding, (c) household contributions to the National Hospital Insurance Fund (NHIF), (d) household contributions to private health insurance companies, and (d) out‐of‐pocket (OOP) payments at points of care.

The first nationally representative survey of 2015 found an age‐standardized DM prevalence of 2.4% with 3.1% of Kenya\'s population having impaired fasting glycemia.[12](#hpm2905-bib-0012){ref-type="ref"}, [16](#hpm2905-bib-0016){ref-type="ref"} The increasing prevalence and the chronic nature of DM makes it a costly disease both to Kenya\'s health system and the affected households as it has been shown that persons with diabetes incur up to three times higher medical costs compared with nondiabetics.[17](#hpm2905-bib-0017){ref-type="ref"}, [18](#hpm2905-bib-0018){ref-type="ref"}, [19](#hpm2905-bib-0019){ref-type="ref"} In addition, delay in diagnosis, poor quality of care or the lack thereof, presence and severity of complications, and comorbid conditions are the most important factors related to DM care costs.[20](#hpm2905-bib-0020){ref-type="ref"}, [21](#hpm2905-bib-0021){ref-type="ref"}

Evidence of patient costs associated with DM care is needed to assess the economic impact of DM to households, the extent to which DM patients and households are protected from financial hardship due to health care use and to design effective financial risk protection mechanisms for this group of patients.[6](#hpm2905-bib-0006){ref-type="ref"}, [21](#hpm2905-bib-0021){ref-type="ref"}, [22](#hpm2905-bib-0022){ref-type="ref"} We therefore conducted this study to document the patient costs of DM at primary care level in Kenya.

2. METHODS {#hpm2905-sec-0006}
==========

2.1. Study setting {#hpm2905-sec-0007}
------------------

The study was conducted from June to December 2017 in two sites in Kenya (Kilifi and Bungoma County) purposively selected to reflect a diverse set of demographic, socio‐economic, and geographical settings. Kilifi is located on the coast of Kenya, and a high burden of stroke and heart failure has been described in this area.[23](#hpm2905-bib-0023){ref-type="ref"} The population in Kilifi has been well characterized by data from the health and demographic surveillance system run by the KEMRI Wellcome Trust Research Programme.[24](#hpm2905-bib-0024){ref-type="ref"} The Webuye Health and Demographic Surveillance System run by Moi University is located in Bungoma County in the western region of Kenya.[25](#hpm2905-bib-0025){ref-type="ref"} Multiple cardiovascular risk factors have been identified in this area.[26](#hpm2905-bib-0026){ref-type="ref"} Table [1](#hpm2905-tbl-0001){ref-type="table"} outlines the study site characteristics.

###### 

Selected study site indicators in 2017

  County    Estimated Population                               No. of Public Hospitals[27](#hpm2905-bib-0027){ref-type="ref"}    No. of Health Centers and Dispensaries[27](#hpm2905-bib-0027){ref-type="ref"}  No. of OPD Patients   No. of Admissions   No. of Diabetes Cases   No. of Hypertension Cases
  --------- -------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------- --------------------- ------------------- ----------------------- ---------------------------
  Bungoma   1 759 499[28](#hpm2905-bib-0028){ref-type="ref"}   9                                                                                                      125                                       1 215 525             70 665              3038                    15 908
  Kilifi    1 466 856[29](#hpm2905-bib-0029){ref-type="ref"}   5                                                                                                      123                                       1 243 315             28 746              4663                    26 458

(all data except where otherwise indicated[30](#hpm2905-bib-0030){ref-type="ref"}).

Six public health care facilities were purposively selected in consultation with county health officials in respective counties to generate a sample of facilities with different workloads, plus the location of the clinics relative to the communities served. However, due to the 150‐day nation‐wide nurses\' strike at the time of data collection,[27](#hpm2905-bib-0027){ref-type="ref"} data were collected from five facilities unlike the anticipated six facilities in the two counties. In Kilifi, a public hospital and a health center that provided DM treatment were selected, while in Bungoma, three public hospitals were sampled. For this descriptive analysis, data from all the facilities were pooled.

2.2. Sample size and sampling {#hpm2905-sec-0008}
-----------------------------

The target enrolment was 282 patients for a sample size sufficient to obtain an estimate of DM patient costs based on the formulae by Kirkwood[28](#hpm2905-bib-0028){ref-type="ref"}: $$\mathsf{N} = \left( {\mathsf{Z}_{\mathsf{\alpha}/2} + \mathsf{Z}_{\mathsf{\beta}}} \right)^{2}*\left( {\mathsf{P}\ \left( {1–\mathsf{P}} \right)} \right)/\mathsf{e}^{2})$$where *Z* ~α/2~ is the critical value of the normal distribution at *α*/2 (for a confidence level of 95%, *α* is .05 and the critical value is 1.96), *Z* ~*β*~ is the critical value of the normal distribution at *β* (for a power of 80%, *β* is 0.2 and the critical value is 0.84), *P* is the expected true proportion of DM in the population in Kenya of 10% (0.10), and *e* is the desired standard size of standard error around the estimated proportion of 5% (±0.05).

Every DM patient receiving treatment and available at participating facilities during data collection was approached to participate in the study. Patients were eligible if they self‐reported DM diagnosis, had received treatment for a minimum of 6 months after diagnosis and were more than 18 years of age. Consenting patients were selected based on meeting the eligibility criteria and the order of arrival at the clinic. Respondents were asked to report on their health service use, associated costs, income, and coping mechanisms if they undertook any of the following to meet DM care costs: borrowing (having taken a loan), selling household items or assets (eg, livestock), and use of savings.

2.3. Measuring patient costs {#hpm2905-sec-0009}
----------------------------

The cost‐of‐illness approach was used to document patient costs.[29](#hpm2905-bib-0029){ref-type="ref"} Interviews were conducted using a structured questionnaire. Three trained interviewers collected the data in the two study sites following a pilot from a facility in Kilifi that was not selected in the main study. Interviews were conducted primarily in Kiswahili, with local languages (Kigiriama and Kibukusu in Kilifi and Bungoma, respectively) used to clarify questions where necessary. Respondents were asked about costs incurred for different care‐seeking episodes described in Table [2](#hpm2905-tbl-0002){ref-type="table"}.

###### 

Care‐seeking episodes included in patient cost estimates

  Care‐seeking Episode               Description                                                                                                                                               Recall Period
  ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  Sick visit                         Cost of current care seeking (during interview), and any out‐patient visit when the patient was ill due to DM outside the scheduled clinic appointments   1 month
  Inpatient visit                    Cost of admission due to DM                                                                                                                               12 months
  Drug collection visit              Cost of regular medicines prescribed to the patient to manage DM                                                                                          Frequency of drug collection, ie, monthly/quarterly
  Laboratory/diagnostic visits       Cost of routine laboratory/diagnostic services done at a health facility                                                                                  Frequency of lab/diagnostic services, ie, monthly/quarterly
  Scheduled clinic check‐up visits   Costs due to regular clinic appointments                                                                                                                  Frequency of clinic appointments, ie, monthly/quarterly

To annuitize sick visit costs, we summed up costs incurred during current care visit and any reported outpatient visit costs that occurred due to DM in the last 4 weeks prior to the study then multiplied by 13 (assuming there are 52 weeks in a year). On the other hand, to annuitize costs in other care‐seeking episodes described in Table [2](#hpm2905-tbl-0002){ref-type="table"}, reported costs were multiplied by the frequency of visits, i.e., weekly, monthly, or quarterly for each episode. Furthermore, any inpatient admission costs in the last 1 year were also collected. Overall DM care costs for all care‐seeking episodes were calculated by summing up the annual costs in each care‐seeking episode. Costs incurred by patients in the overall sample, costs incurred by diabetics without comorbidities (hereafter called diabetes‐only patients), and costs incurred by diabetics with comorbidities (hereafter called comorbid patients), i.e., patients who reported both DM and hypertension diagnosis, were analysed and reported separately.

For each of the care‐seeking episode, two broad cost categories were estimated: direct OOP costs and indirect (productivity losses) costs for both patients and their caregivers. Direct health care costs included any charges levied for medicines and user fees, i.e., registration, consultation, and laboratory services. Direct non--health care costs included transport costs to and from a health provider and any costs associated with food or accommodation while seeking care. For this analysis, OOP costs were defined as the sum of direct health care and direct non--health care costs. The analysis was restricted to patients who reported any OOP costs for each care‐seeking episode.

Indirect costs were estimated based on the total hours lost while seeking care as well as the cost of illness‐related to lost productivity for both patients and their caregivers, assuming that these hours would have been used for productive activity in the absence of DM.[30](#hpm2905-bib-0030){ref-type="ref"} Income lost due to DM illness was therefore estimated by multiplying the estimated number of lost production hours due to DM by the official minimum wage; by the official minimum wage of Kenya shillings (KES) 8568 (US\$ 84/month) in the agricultural sector in 2017 (given the main economic activities in our study sites).[31](#hpm2905-bib-0031){ref-type="ref"} We assumed an average workday of 8 h/day and 22 working days/month. Caregivers\' lost productivity was also estimated by multiplying the total number of hours spent caring for the patient by the official minimum wage rate.

Income was estimated by asking detailed questions about income categories, including patient income, income for household members, welfare payments, and government assistance. As a measure of financial risk protection, we compared total direct costs incurred in the overall sample and by socio‐economic status, against annual household income and total direct costs excluding transportation costs and defined costs as catastrophic if they exceeded 10% of annual household income.[32](#hpm2905-bib-0032){ref-type="ref"}

2.4. Data management and analysis {#hpm2905-sec-0010}
---------------------------------

Data were double entered to enhance data quality. The two data sets were compared to eliminate data entry errors. Consistency and range checks were used to ensure the completeness of data. Data were analysed using STATA 14.0 (STATA, StataCorp, Texas). Frequency counts and percentages were used to describe patient demographic and socio‐economic variables. Due to skewed nature of costs data, mean and median values were reported for all cost estimates as a measure of central tendency and 95% confidence intervals (CI) and interquartile range (IQR) were reported. Cost results are presented in KES and US Dollars (US\$). Cost in KES was converted to US\$ using the following exchange rate: US\$ 1 = KES 102 (average exchange rate, January‐December 2017).[33](#hpm2905-bib-0033){ref-type="ref"}

2.5. Ethical approval {#hpm2905-sec-0011}
---------------------

Ethical approval for the study was obtained from the Scientific Ethics Review Unit (SERU) of KEMRI (Ref: KEMRI/SERU/CGMR‐C/041/3270) and from the County Department of Health in both study sites. Written consent was obtained from each participant. Facility managers were informed about the study and granted permission to access clinics and patients.

3. RESULTS {#hpm2905-sec-0012}
==========

3.1. Participants characteristics and health services utilization {#hpm2905-sec-0013}
-----------------------------------------------------------------

Overall, 163 patients were interviewed: 92 (56.4%) from Bungoma and 71 (43.6%) from Kilifi. The mean age in the sample was 58.9 years, and 58.9% of the respondents were female. More than half of the patients reported hypertension comorbidity (57.7%), were not enrolled to any health insurance scheme (68.1%), and slightly under half were diagnosed with either DM or hypertension (HTN) more than 5 years ago (47.9%) (Table [3](#hpm2905-tbl-0003){ref-type="table"}). The median travel time to a health facility was 30 minutes (IQR, 18‐60). Forty‐five patients (27.6%) reported that the facility where they sought care was not the nearest to them; of these, 48.9% (95% CI, 34.2‐63.7) reported lack of resources such as medicines and/or diagnostic equipment, 37.8% (95% CI, 24.5‐53.2) reported referral, and 13.3% (95% CI, 5.9‐27.3) reported other reasons (eg, time consuming to wait) for not visiting the nearest facility.

###### 

Patient characteristics

  Characteristic                           Observations (n = 163)   Proportion (95% CI)
  ---------------------------------------- ------------------------ ---------------------
  Mean age in years                        163                      58.9 (56.8‐61.0)
  Gender                                                            
  Male                                     67                       41.1% (33.7‐48.9)
  Female                                   96                       58.9% (51.1‐66.2)
  Illness condition                                                 
  Diabetes mellitus                        69                       42.3% (34.9‐50.1)
  Diabetes mellitus & Hypertension         94                       57.7% (49.9‐65.1)
  Enrolled to a health insurance scheme                             
  Yes                                      52                       31.9% (25.1‐39.5)
  No                                       111                      68.1% (60.5‐74.9)
  Employment status                                                 
  Formal employment                        32                       19.6 (14.2‐26.5)
  Informal/unemployed                      131                      80.4 (73.5‐85.8)
  Reason for not working                                            
  Related to DM/DM & HTN comorbidity       48                       29.4% (22.9‐37.0)
  Not related to DM/DM & HTN comorbidity   115                      70.6% (63.0‐77.1)
  Highest level of education                                        
  None                                     27                       16.6% (11.6‐23.2)
  Primary                                  66                       40.5% (33.2‐48.3)
  Secondary                                47                       28.8% (22.3‐36.3)
  Graduate/certificate                     23                       14.1% (9.5‐20.4)
  Where diagnosed                                                   
  Public facility                          132                      81.0% (74.1‐86.3)
  Mission facility                         7                        4.3% (2.0‐8.7)
  Private facility                         24                       14.7% (10.0‐21.1)
  Illness duration                                                  
  6 mo to \<1 y                            16                       9.8% (6.1‐15.5)
  1‐5 y                                    69                       42.3% (34.9‐50.1)
  ≥5 y                                     78                       47.9% (40.2‐55.6)

3.2. Patient costs associated with health care use {#hpm2905-sec-0014}
--------------------------------------------------

### 3.2.1. Sick visit costs {#hpm2905-sec-0015}

In the overall sample, 36% (n = 59) of patients reported a sick visit, i.e., sought care out of their scheduled clinic appointments a month before the survey. Similarly, 29% (n = 20) of diabetes‐only patients and 41% (n = 39) of comorbid patients reported a sick visit. Mean annual costs for medicines attracted the highest direct cost in the overall sample---KES 15 340.8 (95% CI, 6120‐24 561.6) (US\$ 150.4 \[95% CI, 60‐240.8\]) mainly driven by the contribution of medicine costs for comorbid patients---KES 17 880 (95% CI, 4641.7‐31 118.3) (US\$ 175.3 \[95% CI, 45.5‐305.1\]). However, among diabetes‐only patients, user charges attracted the highest mean annual cost---KES 12 733.5 (95% CI, 1825‐27 292) (US\$ 124.8 \[95% CI, 17.9‐267.6\]) (Table [5](#hpm2905-tbl-0005){ref-type="table"}). Transport costs contributed 25.8% of total costs in the overall sample, 26.3% in the diabetes‐only group, and 25.5% in the comorbid group (Tables [4](#hpm2905-tbl-0004){ref-type="table"}, [5](#hpm2905-tbl-0005){ref-type="table"}, [6](#hpm2905-tbl-0006){ref-type="table"}).

###### 

Overall mean and median annual costs of diabetes care at five public facilities in Kenya (2017 US\$)

  Care‐seeking Episode            Cost Category              n                              Mean KES (95% CI)              Median KES (IQR)      Mean US\$ (95% CI)    Median US\$ (IQR)   As a % of Total Direct Costs
  ------------------------------- -------------------------- ------------------------------ ------------------------------ --------------------- --------------------- ------------------- ------------------------------
  Sick visit                      Direct health care costs                                                                                                                                 
  User charges                    59                         7435.8 (2611.2‐12 260.4)       4549.2 (1173.0‐6497.4)         72.9 (25.6‐120.2)     44.6 (11.5‐63.7)      23.9                
  Medicines                       59                         15 340.8 (6120‐24 561.6)       5202.0 (1815.6‐12 872.4)       150.4 (60.0‐240.8)    51.0 (17.8‐126.2)     49.3                
  Direct non--health care costs                                                                                                                                                            
  Transport                       59                         8037.6 (4845‐11 220)           5202 (1815.6‐9098.4)           78.8 (47.5‐110.0)     51.0 (17.8‐89.2)      25.8                
  Food                            59                         326.4 (10.2‐632.4)             0                              3.2 (0.1‐6.2)         0                     1.0                 
  Subtotal (direct costs)         59                         31 130.4 (18 961.8‐43 299.0)   17 156.4 (8578.2‐32 762.4)     305.2 (185.9‐424.5)   168.2 (84.1‐321.2)                        
  Indirect costs                  59                         7466.4 (6262.8‐8659.8)         6344.4 (3906.6‐8884.2)         73.2 (61.4‐84.9)      62.2 (38.3‐87.1)                          
  Direct + Indirect costs         59                         38 596.8 (25 928.4‐51 265.2)   24 388.2 (12 923.4‐41 524.2)   378.4 (254.2‐502.6)   239.1 (126.7‐407.1)                       
  In‐patient admission            Direct health care costs                                                                                                                                 
  User charges                    16                         16 717.8 (3264.0‐30 161.4)     7170.6 (2203.2‐15 330.6)       163.9 (32.0‐295.7)    70.3 (21.6‐150.3)     64.5                
  Medicines                       11                         4008.6 (1366.8‐6660.6)         3468 (683.4‐8496.6)            39.3 (13.4‐65.3)      34.0 (6.7‐83.3)       10.6                
  Direct non--health care costs                                                                                                                                                            
  Transport                       36                         1917.6 (703.8‐3131.4)          938.4 (418.2‐1734.0)           18.8 (6.9‐30.7)       9.2 (4.1‐17.0)        16.6                
  Food                            17                         2019.6 (204.0‐3825.0)          795.6 (499.8‐1999.2)           19.8 (2.0‐37.5)       7.8 (4.9‐19.6)        8.3                 
  Subtotal (direct costs)         36                         11 526.0 (3825‐19 216.8)       2478.6 (765.0‐14 932.8)        113.0 (37.5‐188.4)    24.3 (7.5‐146.4)                          
  Indirect costs                  37                         4804.2 (3376.2‐6242.4)         3417.0 (1662.6‐6058.8)         47.1 (33.1‐61.2)      33.5 (16.3‐59.4)                          
  Direct + Indirect costs         37                         16 014.0 (7548.0‐24 490.2)     6507.6 (3498.6‐20 094.0)       157.0 (74.0‐240.1)    63.8 (34.3‐197.0)                         
  Medicine collection             Direct health care costs                                                                                                                                 
  Medicines                       135                        13 300.8 (9608.4‐16 983.0)     5997.6 (3243.6‐13 198.8)       130.4 (94.2‐166.5)    58.8 (31.8‐129.4)     87.3                
  Direct non--health care costs                                                                                                                                                            
  Transport                       22                         9690.0 (5385.6‐13 984.2)       7201.2 (2397.0‐14 402.4)       95.0 (52.8‐137.1)     70.6 (23.5‐141.2)     10.4                
  Food                            8                          5936.4 (4304.4‐7568.4)         7201.2 (4845.0‐7201.2)         58.2 (42.2‐74.2)      70.6 (47.5‐70.6)      2.3                 
  Subtotal (direct costs)         136                        15 116.4 (11 189.4‐19 043.4)   8404.8 (3600.6‐15 595.8)       148.2 (109.7‐186.7)   82.4 (35.3‐152.9)                         
  Indirect costs                  163                        8017.2 (6446.4‐9598.2)         5273.4 (3419.2‐9373.8)         78.6 (63.2‐94.1)      51.7 (33.5‐91.9)                          
  Direct + Indirect costs         163                        20 634.6 (16 503.6‐24 765.6)   12 739.8 (5803.8‐23 133.6)     202.3 (161.8‐242.8)   124.9 (56.9‐226.8)                        
  Diagnostic visit                Direct health care costs                                                                                                                                 
  Test cost                       118                        5222.4 (2029.8‐8404.8)         1795.2 (1795.2‐3600.6)         51.2 (19.9‐82.4)      17.6 (17.6‐35.3)      80.8                
  Direct non--health care costs                                                                                                                                                            
  Transport                       21                         5844.6 (4192.2‐7486.8)         4804.2 (2397.0‐9598.2)         57.3 (41.1‐73.4)      47.1 (23.5‐94.1)      16.1                
  Food                            7                          3396.6 (1601.4‐5181.6)         3600.6 (2397.0‐3600.6)         33.3 (15.7‐50.8)      35.3 (23.5‐35.3)      3.1                 
  Subtotal (direct costs)         122                        6252.6 (3111.0‐9384.0)         1795.2 (1795.2‐3600.6)         61.3 (30.5‐92.0)      17.6 (17.6‐35.3)                          
  Indirect costs                  161                        4885.8 (4222.8‐5548.8)         3886.2 (2641.8‐5865.0)         47.9 (41.4‐54.4)      38.1 (25.9‐57.5)                          
  Direct + Indirect costs         161                        9618.6 (7068.6‐12 168.6)       5661.0 (3825.0‐9455.4)         94.3 (69.3‐119.3)     55.5 (37.5‐92.7)                          
  Scheduled clinics               Direct health care costs                                                                                                                                 
  User charges                    128                        4610.4 (2723.4‐6507.6)         2998.8 (2397.0‐4141.2)         45.2 (26.7‐63.8)      29.4 (23.5‐40.6)      24.1                
  Medicines                       122                        10 159.2 (7170.6‐13 147.8)     5967.0 (2397.0‐11 995.2)       99.6 (70.3‐128.9)     58.5 (23.5‐117.6)     50.5                
  Direct non--health care costs                                                                                                                                                            
  Transport                       144                        3957.6 (3325.2‐4579.8)         2397.0 (1203.6‐4804.2)         38.8 (32.6‐44.9)      23.5 (11.8‐47.1)      23.2                
  Food                            11                         4834.8 (397.8‐9271.8)          2397.0 (1795.2‐4804.2)         47.4 (3.9‐90.9)       23.5 (17.6‐47.1)      2.2                 
  Subtotal (direct costs)         163                        15 045.0 (12 056.4‐18 023.4)   9843.0 (4804.2‐17 401.2)       147.5 (118.2‐176.7)   96.5 (47.1‐170.6)                         
  Indirect costs                  163                        4396.2 (3957.6‐4824.6)         3519.0 (2611.2‐5865.0)         43.1 (38.8‐47.3)      34.5 (25.6‐57.5)                          
  Direct + Indirect costs         163                        19 441.2 (16 207.8‐22 664.4)   14 259.6 (7476.6‐23 878.2)     190.6 (158.9‐222.2)   139.8 (73.3‐234.1)                        
  Overall costs                   Direct health care costs                                                                                                                                 
  User charges                    135                        11 413.8 (6987.0‐15 840.6)     6293.4 (5467.2‐9251.4)         111.9 (68.5‐155.3)    61.7 (53.6‐90.7)      17.5                
  Medicines                       138                        33 374.4 (25 092.0‐41 656.8)   19 818.6 (8404.8‐38 403.0)     327.2 (246.0‐408.4)   194.3 (82.4‐376.5)    52.4                
  Direct non--health care costs                                                                                                                                                            
  Transport                       147                        12 168.6 (9894.0‐14 433.0)     7599.0 (3702.6‐14 800.2)       119.3 (97.0‐141.5)    74.5 (36.3‐145.1)     22.6                
  Food                            31                         6232.2 (2743.8‐9720.6)         2397.0 (7956.0‐6497.4)         61.1 (26.9‐95.3)      23.5 (78.0‐63.7)      7.5                 
  Subtotal (direct costs)         163                        53 907.0 (43 625.4‐64 188.6)   35 802.0 (16 462.8‐59 884.2)   528.5 (427.7‐629.3)   351.0 (161.4‐587.1)                       
  Indirect costs                  163                        23 174.4 (20 910.0‐25 438.8)   19 216.8 (13 963.8‐28 417.2)   227.2 (205.0‐249.4)   188.4 (136.9‐278.6)                       
  Direct + Indirect costs         163                        77 081.4 (65 820.6‐88 342.2)   58 415.4 (33 966.0‐90 922.8)   755.7 (645.3‐866.1)   572.7 (333.0‐891.4)                       

###### 

Mean and median annual cost for diabetes‐only patients at five public facilities in Kenya (2017 US\$)

  Care‐seeking Episode            Cost Category              n                              Mean KES (95% CI)              Median KES (IQR)      Mean US\$ (95% CI)    Median US\$ (IQR)
  ------------------------------- -------------------------- ------------------------------ ------------------------------ --------------------- --------------------- -------------------
  Sick visit                      Direct health care costs                                                                                                             
  User charges                    20                         12 733.5 (1825.0‐27 292.0)     3055.0 (845.0‐6110.0)          124.8 (17.9‐267.6)    30.0 (8.3‐59.9)       40.6
  Medicines                       20                         10 387 (488.6‐20 305.4)        2340 (520‐9425)                101.8 (4.8‐199.1)     22.9 (5.1‐92.4)       33.1
  Direct non--health care costs                                                                                                                                        
  Transport                       20                         8268 (3090.8‐13 445.2)         3120 (1560‐9100)               81.1 (30.3‐131.8)     30.6 (15.3‐89.2)      26.3
  Food                            20                         0                              0                              0                     0                     0.0
  Subtotal (direct costs)         20                         31 388.5 (7168.3‐55 608.7)     10 335 (6630‐33 605)           307.7 (70.3‐545.2)    101.3 (65.0‐329.5)    
  Indirect costs                  20                         7360.5 (4925.0‐9796.1)         4545.6 (3860.0‐10 713.2)       72.2 (48.3‐96.0)      44.6 (37.8‐105.0)     
  Direct + Indirect costs         20                         38 749.0 (14 080.6‐63 417.5)   18 804.3 (11 197.4‐42 818.0)   379.9 (138.0‐621.7)   184.4 (109.8‐419.8)   
  In‐patient admission            Direct health care costs                                                                                                             
  User charges                    7                          18 568.6 (11 234.9‐48 372.1)   4700 (3150‐16 000)             182.0 (110.1‐474.2)   46.1 (30.9‐156.9)     76.8
  Medicines                       5                          3372 (1624.9‐8368.9)           1200 (1110‐4350)               33.1 (15.9‐82.0)      11.8 (10.9‐42.6)      10.0
  Direct non--health care costs                                                                                                                                        
  Transport                       15                         910.7 (225.3‐1596.1)           600 (200‐1080)                 8.9 (2.2‐15.6)        5.9 (2.0‐10.6)        8.1
  Food                            6                          1441.7 (265.4‐2618.0)          850 (750‐2500)                 14.1 (2.6‐25.7)       8.3 (7.4‐24.5)        5.1
  Subtotal (direct costs)         15                         11 276.7 (3958.3‐26 511.7)     1860 (400‐7130)                110.6 (38.8‐259.9)    18.2 (3.9‐69.9)       
  Indirect costs                  15                         5060.3 (2042.4‐8078.2)         3101.0 (1611.6‐6006.7)         49.6 (20.0‐79.2)      30.4 (15.8‐58.9)      
  Direct + Indirect costs         15                         16 337.0 (1514.0‐34 187.9)     5968.5 (2567.1‐14 181.8)       160.2 (14.8‐335.2)    58.5 (25.2‐139.0)     
  Medicine collection             Direct health care costs                                                                                                             
  Medicines                       57                         9230.5 (6253.9‐12 207.1)       5040 (2400‐10 680)             90.5 (61.3‐119.7)     49.4 (23.5‐104.7)     84.7
  Direct non--health care costs                                                                                                                                        
  Transport                       8                          10 950 (581.6‐22 481.6)        6000 (2400‐13 800)             107.4 (5.7‐220.4)     58.8 (23.5‐135.3)     14.1
  Food                            1                          7200                           7200                           70.6                  70.6                  1.2
  Subtotal (direct costs)         57                         10 893.7 (6884.9‐14 902.5)     6000 (3360‐12 000)             106.8 (67.5‐146.1)    58.8 (32.9‐117.6)     
  Indirect costs                  69                         7771.4 (4800.1‐10 742.7)       4688.2 (3223.1‐7325.3)         76.2 (47.1‐105.3)     46.0 (31.6‐71.8)      
  Direct + Indirect costs         69                         16 770.6 (11 672.9‐21 868.2)   10 395.2 (5225.2‐16 739.7)     164.4 (114.4‐214.4)   101.9 (51.2‐164.1)    
  Diagnostic visit                Direct health care costs                                                                                                             
  Test cost                       47                         7598.3 (201.4‐15 398.0)        1800 (1800‐3600)               74.5 (2.0‐151.0)      17.6 (17.6‐35.3)      90.6
  Direct non--health care costs                                                                                                                                        
  Transport                       7                          4971.4 (2075.4‐7867.5)         4800 (2400‐7200)               48.7 (20.3‐77.1)      47.1 (23.5‐70.6)      8.8
  Food                            1                          2400                           2400                           23.5                  23.5                  0.6
  Subtotal (direct costs)         50                         7886.4 (572.7‐15 200.1)        1800 (1800‐3600)               77.3 (5.6‐149.0)      17.6 (17.6‐35.3)      
  Indirect costs                  68                         4423.4 (3644.7‐5202.1)         3850.2 (2607.8‐4887.4)         43.4 (35.7‐51.0)      37.7 (25.6‐47.9)      
  Direct + Indirect costs         68                         10 222.2 (4827.4‐15 616.9)     5682.4 (3809.1‐9273.8)         100.2 (47.3‐153.1)    55.7 (37.3‐90.9)      
  Scheduled clinics               Direct health care costs                                                                                                             
  User charges                    55                         6362.2 (1953.2‐10 771.1)       3000 (2400‐4080)               62.4 (19.1‐105.6)     29.4 (23.5‐40.0)      38.6
  Medicines                       50                         6289.2 (4546.0‐8032.4)         4350 (2400‐9000)               61.7 (44.6‐78.7)      42.6 (23.5‐88.2)      34.7
  Direct non--health care costs   69                         13 148.7 (9166.8‐17 130.6)     9000 (4080‐17 640)             128.9 (89.9‐167.9)    88.2 (40‐172.9)       
  Transport                       62                         3878.7 (2987.6‐4769.8)         2400 (1200‐4800)               38.0 (29.3‐46.8)      23.5 (11.8‐47.1)      26.5
  Food                            1                          2400                           2400                           23.5                  23.5                  0.3
  Subtotal (direct costs)         69                         13 148.7 (9166.8‐17 130.6)     9000 (4080‐17 640)             128.9 (89.9‐167.9)    88.2 (40‐172.9)       
  Indirect costs                  69                         4071.1 (3542.5‐4599.6)         3516.1 (2344.1‐5086.7)         39.9 (34.7‐45.1)      34.5 (23.0‐49.9)      
  Direct + Indirect costs         69                         17 219.8 (13 072.6‐21 366.9)   12 792.3 (6876.1‐21 156.1)     168.8 (128.2‐209.5)   125.4 (67.4‐207.4)    
  Overall costs                   Direct health care costs                                                                                                             
  User charges                    58                         14 839.1 (4730.7‐24 947.6)     6250 (5000‐7880)               145.5 (46.4‐244.6)    61.3 (49.0‐77.3)      30.3
  Medicines                       57                         22 275.3 (16 647.7‐27 902.8)   18 400 (7400‐30 500)           218.4 (163.2‐273.6)   180.4 (75.5‐299.0)    44.0
  Direct non--health care costs                                                                                                                                        
  Transport                       63                         11 218.4 (7919.4‐14 517.5)     6300 (3360‐14 640)             110.0 (77.6‐142.3)    61.8 (32.9‐143.5)     24.7
  Food                            9                          3016.7 (609.4‐5423.9)          2400 (800‐3200)                29.6 (6.0‐53.2)       23.5 (7.8‐31.4)       1.0
  Subtotal (direct costs)         69                         46 754.4 (31 008.3‐62 500.4)   31 500 (13 880‐50 840)         458.4 (304.0‐612.7)   308.8 (136.1‐498.4)   
  Indirect costs                  64                         21 861.1 (18 070.1‐25 652.1)   17 483.0 (13 136.7‐26 187.8)   214.3 (177.2‐251.5)   171.4 (128.8‐256.7)   
  Direct + Indirect costs         69                         68 615.5 (51472.6‐85 758.3)    52 372.5 (28 458.9‐75 288.0)   672.7 (504.6‐840.8)   513.5 (279.0‐738.1)   

###### 

Mean and median annual cost for comorbid (diabetes mellitus and hypertension) patients at five public facilities in Kenya (2017 US\$)

  Care‐seeking Episode            Cost Category              n                              Mean KES (95% CI)               Median KES (IQR)      Mean US\$ (95% CI)    Median US\$ (IQR)
  ------------------------------- -------------------------- ------------------------------ ------------------------------- --------------------- --------------------- -------------------
  Sick visit                      Direct health care costs                                                                                                              
  User charges                    39                         4720 (3405.9‐6034.1)           5200 (1300‐6500)                46.3 (33.4‐59.2)      51.0 (12.7‐63.7)      15.2
  Medicines                       39                         17 880 (4641.7‐31 118.3)       7670 (3120‐15 600)              175.3 (45.5‐305.1)    75.2 (30.6‐152.9)     57.7
  Direct non--health care costs                                                                                                                                         
  Transport                       39                         7913.3 (3726.5‐12 100.2)       5200 (2600‐9100)                77.6 (36.5‐118.6)     51.0 (25.5‐89.2)      25.5
  Food                            39                         486.7 (22.5‐950.8)             0                               4.8 (0.2‐9.3)         0                     1.6
  Subtotal (direct costs)         39                         31 000 (16 546.6‐45 453.4)     20 800 (10 660‐32 760)          303.9 (162.2‐445.6)   203.9 (104.5‐321.2)   
  Indirect costs                  39                         7515.4 (6110.2‐8920.6)         6856.5 (4063.1‐8888.0)          73.7 (59.9‐87.5)      67.2 (39.8‐87.1)      
  Direct + Indirect costs         39                         38 515.4 (23 247.1‐53 783.7)   29 688.0 (15 563.4‐41 037.2)    377.6 (227.9‐527.3)   291.1 (152.6‐402.3)   
  In‐patient admission            Direct health care costs                                                                                                              
  User charges                    9                          15 273.9 (287.2‐30 834.9)      9990 (1000‐14 660)              149.7 (2.8‐302.3)     97.9 (9.8‐143.7)      56.0
  Medicines                       6                          4545.8 (166.7‐8924.9)          3598.5 (680‐8500)               44.6 (1.6‐87.5)       35.3 (6.7‐83.3)       11.1
  Direct non--health care costs                                                                                                                                         
  Transport                       21                         2633.3 (592.3‐4674.4)          1200 (800‐2400)                 25.8 (5.8‐45.8)       11.8 (7.8‐23.5)       22.5
  Food                            11                         2331.8 (589.9‐5253.5)          600 (300‐2000)                  22.9 (5.8‐51.5)       5.9 (2.9‐19.6)        10.4
  Subtotal (direct costs)         21                         11 699.5 (2885.6‐20 513.4)     2750 (1180‐15 960)              114.7 (28.3‐201.1)    27.0 (11.6‐156.5)     
  Indirect costs                  22                         4633.5 (3108.5‐6158.5)         4248.7 (1660.4‐6187.4)          45.4 (30.5‐60.4)      41.7 (16.3‐60.7)      
  Direct + Indirect costs         22                         15 801.2 (6790.6‐24 811.9)     7149.1 (4060.4‐20 634.9)        154.9 (66.6‐243.3)    70.1 (39.8‐202.3)     
  Medicine collection             Direct health care costs                                                                                                              
  Medicines                       78                         16 269.2 (10 291.7‐22 246.8)   7200 (3600‐15 000)              159.5 (100.9‐218.1)   70.6 (35.3‐147.1)     88.4
  Direct non--health care costs                                                                                                                                         
  Transport                       14                         8965.7 (4969.6‐12 961.8)       7200 (4800‐14 400)              87.9 (48.7‐127.1)     70.6 (47.1‐141.2)     8.7
  Food                            7                          5760 (3876.6‐7643.4)           7200 (4800‐7200)                56.5 (38.0‐74.9)      70.6 (47.1 (70.6)     2.8
  Subtotal (direct costs)         79                         18 162.5 (12 069.3‐24 255.8)   9120 (4320‐18 000)              178.1 (118.3‐237.8)   89.4 (42.4‐176.5)     
  Indirect costs                  94                         8205.7 (6515.2‐9896.2)         5860.2 (3809.1‐9962.4)          80.4 (63.9‐97.0)      57.5 (37.3‐97.7)      
  Direct + Indirect costs         94                         23 470.0 (17 351.3‐29 588.6)   14 522.6 (6022.2‐25 785.0)      230.1 (170.1‐290.1)   142.4 (59.0‐252.8)    
  Diagnostic visit                Direct health care costs                                                                                                              
  Test cost                       71                         3643.9 (2132.2‐5155.7)         1800 (1800‐3600)                35.7 (20.9‐50.5)      17.6 (17.6‐35.3)      70.3
  Direct non--health care costs                                                                                                                                         
  Transport                       14                         6274.3 (4030.7‐8517.8)         7200 (2400‐9600)                61.5 (39.5‐83.5)      70.6 (23.5‐94.1)      23.9
  Food                            6                          3560 (1390.9‐5729.1)           3600 (2400‐3600)                34.9 (13.6‐56.2)      35.3 (23.5‐35.3)      5.8
  Subtotal (direct costs)         72                         5110.0 (3282.5‐6937.4)         1800 (2400‐4080)                50.1 (32.2‐68.0)      17.6 (23.5‐40.0)      
  Indirect costs                  93                         5220.8 (4221.9‐6219.6)         4102.2 (2695.7‐6153.2)          51.2 (41.4‐61.0)      40.2 (26.4‐60.3)      
  Direct + Indirect costs         93                         9176.9 (7078.3‐11 275.4)       5609.1 (4102.2‐10 060.2)        90.0 (69.4‐110.5)     55.0 (40.2‐98.6)      
  Scheduled clinics               Direct health care costs                                                                                                              
  User charges                    73                         3292.6 (2909.4‐3675.7)         3000 (2640‐4200)                32.3 (28.5‐36.0)      29.4 (25.9‐41.2)      15.6
  Medicines                       72                         12 839.2 (7966.7‐17 711.6)     7200 (3300‐13 200)              125.9 (78.1‐173.6)    70.6 (32.4‐129.4)     59.8
  Direct non--health care costs   94                         16 432.2 (12 120.0‐20 744.5)   10 560 (5640‐17 400)            161.1 (118.8‐203.4)   103.5 (55.3‐170.6)    
  Transport                       82                         4013.3 (3125.5‐4901.0)         2400 (1200‐4800)                39.3 (30.6‐48.0)      23.5 (11.8‐47.1)      21.3
  Food                            10                         5076 (134.9‐10 017.1)          2640 (1800‐4800)                49.8 (1.3‐98.2)       25.9 (17.6 (47.1)     3.3
  Subtotal (direct costs)         94                         16 432.2 (12 120‐20 744.5)     10 560 (5640‐17 400)            161.1 (118.8‐203.4)   103.5 (55.3‐170.6)    
  Indirect costs                  94                         4632.5 (3985.5‐5279.4)         3516.1 (2695.7‐5860.2)          45.4 (39.1‐51.8)      34.5 (26.4‐57.4)      
  Direct + Indirect costs         94                         21 064.7 (16 336.1‐25 793.2)   15 255.1 (8769.4‐24 164.3)      206.5 (160.2‐252.9)   149.6 (86.0‐236.9)    
  Overall costs                   Direct health care costs                                                                                                              
  User charges                    77                         8837.2 (6958.2‐10 716.1)       7500 (5500‐9400)                86.6 (68.2‐105.1)     73.5 (53.9‐92.2)      12.9
  Medicines                       81                         41 187.2 (27 764.2‐54 610.1)   21 900 (10 300‐42 700)          403.8 (272.2‐535.4)   214.7 (101.0‐418.6)   63.3
  Direct non--health care costs                                                                                                                                         
  Transport                       84                         12 873.2 (9710.5‐16 035.9)     8340 (3800‐15 300)              126.2 (95.2‐157.2)    81.8 (37.3‐150)       20.5
  Food                            24                         7438.3 (2701.2‐12 175.4)       2300 (725‐10 100)               72.9 (26.5‐119.4)     22.5 (7.1‐99.0)       3.3
  Subtotal (direct costs)         94                         59 161.8 (45 440.9‐72 882.8)   42 750 (17 162‐65 550)          580.0 (445.5‐714.5)   419.1 (168.3‐642.6)   
  Indirect costs                  94                         24 137.9 (21 314.9‐26 960.9)   20 571.8 (15 090.0‐29 984.8)    236.6 (209.0‐264.3)   201.2 (147.9‐294.0)   
  Direct + Indirect costs         94                         83 299.8 (68 223.5‐98 376.0)   63 970.6 (37 833.6‐100 271.8)   816.7 (668.9‐964.5)   627.2 (370.9‐983.1)   

### 3.2.2. Inpatient costs {#hpm2905-sec-0016}

Twenty‐two percent (n = 37) of the patients in the study reported an inpatient admission in the past year with each admission lasting a mean of 1.6 days (95% CI, 1.3‐1.9). User charges constituted the highest direct costs attracting an estimated KES 16 718.8 (95% CI, 3264‐30 161.4) (US\$ 163.9 \[95% CI, 32‐295.7\]), KES 18 568.6 (95% CI, 11 234.9‐48 372.1) (US\$ 182.0 \[95% CI, 110.1‐474.2\]), and KES 15 273.9 (95% CI, 287.2‐30 834.9) (US\$ 149.7 \[95% CI, 2.8‐302.3\]) mean annual costs in the overall sample, diabetes‐only patients, and comorbid patients, respectively. Additionally, direct costs were higher than indirect costs in all the three groups (Tables [4](#hpm2905-tbl-0004){ref-type="table"}, [5](#hpm2905-tbl-0005){ref-type="table"}, [6](#hpm2905-tbl-0006){ref-type="table"}).

### 3.2.3. Medicine collection costs {#hpm2905-sec-0017}

The median number of routine medicines prescribed to diabetes‐only patients was 2 (IQR 1‐2) and 3 (IQR, 3‐4) for comorbid patients. The most expensive antidiabetic regimen was metformin and insulin (mean annual cost KES 15 636.6 (95% CI, 2723.4‐28 539.6) (US\$ 153.3 \[95% CI, 26.7‐279.8\]) while metformin, glibenclamide, and enalapril combinations were the most expensive medicines prescribed to comorbid patients---mean annual cost KES 18 635.4 (95% CI, 3131.4‐40 402.2) (US\$ 182.7 \[95% CI, 30.7‐396.1\]) (Table [7](#hpm2905-tbl-0007){ref-type="table"}). In addition, more than half (57.7%) of sampled patients reported obtaining their routine medicines from a public hospital (Figure [1](#hpm2905-fig-0001){ref-type="fig"}). Medicines accounted for 87.3% of total OOP costs during medicine collection visits while transport and food accounted for 10.4% and 2.3% in the overall sample, respectively (Table [4](#hpm2905-tbl-0004){ref-type="table"}).

###### 

Medicines costs

  Drug Name                                                                 n    Mean KES (95% CI)            Median KES (IQR)             Mean US\$ (95% CI)   Median US\$ (IQR)
  ------------------------------------------------------------------------- ---- ---------------------------- ---------------------------- -------------------- --------------------
  Metformin                                                                 16   8384.4 (2509.2‐14 259.6)     3172.2 (897.6‐13 198.8)      82.2 (24.6‐139.8)    31.1 (8.8‐129.4)
  Metformin + insulin                                                       15   15 636.6 (2723.4‐28 539.6)   10 404.0 (4804.2‐15 004.2)   153.3 (26.7‐279.8)   102.0 (47.1‐147.1)
  Metformin + glibenclamide                                                 63   12 678.6 (6201.6‐19 155.6)   3835.2 (1438.2‐12 484.8)     124.3 (60.8‐187.8)   37.6 (14.1‐122.4)
  Metformin + glibenclamide + nifedipine                                    18   17 554.2 (336.6‐34 771.8)    8160.0 (0.0‐14 881.8)        172.0 (3.3‐340.9)    80.0 (0.0‐145.9)
  Metformin + glibenclamide + enalapril                                     15   18 635.4 (3131.4‐40 402.2)   3600.6 (0.0‐16 320.0)        182.7 (30.7‐396.1)   35.3 (0.0‐160.0)
  Metformin + glibenclamide + hydrochlorothiazide                           21   13 935.6 (1122‐26 270)       5395.8 (1438.2‐13 198.8)     136.6 (11.0‐257.5)   52.9 (14.1‐90.0)
  Metformin + nifedipine + hydrochlorothiazide                              11   16 218.0 (1530.0‐30 895.8)   5457.0 (1438.2‐13 198.8)     159.0 (15.0‐302.9)   53.5 (14.1‐129.4)
  Insulin + other antihypertensives[a](#hpm2905-note-0002){ref-type="fn"}   3    9557.4 (1315.8‐20 430.6)     8404.8 (5875.2‐14 402.4)     93.7 (12.9‐200.3)    82.4 (57.6‐141.2)

Atenolol + losartan + amlodipine.

![Source of medicines](HPM-35-290-g001){#hpm2905-fig-0001}

### 3.2.4. Diagnostic/laboratory test costs {#hpm2905-sec-0018}

The main routine diagnostic tests reported by diabetes‐only patients were fasting blood sugar (FBS) and weight---mean annual cost KES 1499.4 (95% CI, 1030.2‐4029) (US\$ 14.7 \[95% CI, 10.1‐39.5\]) while comorbid patients reported FBS and blood pressure, mean annual cost KES 4518.6 (95% CI, 173.4‐8853.6) (US\$ 44.3 \[95% CI, 1.7‐86.8\]), and echocardiogram and kidney function tests, mean annual cost KES 3335.4 (95% CI, 1081.2‐5589.6) (US\$ 32.7 \[95% CI, 10.6‐54.8\]). The mean annual direct costs for diagnostic/laboratory tests were generally higher for diabetes‐only patients (Table [5](#hpm2905-tbl-0005){ref-type="table"}) compared with comorbid patients (Table [6](#hpm2905-tbl-0006){ref-type="table"}). Moreover, 18% (n = 29) of the patients reported incurring costs to purchase of either glucometers or blood pressure monitoring machines, incurring a mean cost of KES 3542.9 (95% CI, 2724.1‐4361.6) (US\$ 34.7 \[95% CI, 26.7‐42.8\]) with additional mean annual cost of KES 16 885.7 (95% CI, 12 377.3‐21 394.1) (US\$ 165.5 \[95% CI, 121.3‐209.7\]) on consumables like glucose strips and lancets.

### 3.2.5. Scheduled clinic appointment costs {#hpm2905-sec-0019}

Majority of patients (76.7%, n = 125) attended scheduled clinic visits monthly. Medicines attracted the highest cost in the overall sample, mean annual cost KES 10 159.2 (95% CI, 7170.6‐13 147.8) (US\$ 99.6 \[95% CI, 70.3‐128.9\]), and in the comorbid patients, mean annual cost KES 12 839.2 (95% CI, 7966.7‐17 711.6) (US\$ 125.9 \[95% CI, 78.1‐173.6\]). However, user charges attracted the highest cost, mean annual cost KES 6362.2 (95% CI, 1953.2‐10 771.1) (US\$ 62.4 \[95% CI, 19.1‐105.6\]) in the diabetes‐only group during scheduled clinic appointments. In addition, transport costs accounted for 23.2%, 26.5%, and 21.3% of total direct OOP costs in the overall sample, diabetes‐only, and comorbid patients, respectively (Tables [4](#hpm2905-tbl-0004){ref-type="table"}, [5](#hpm2905-tbl-0005){ref-type="table"}, [6](#hpm2905-tbl-0006){ref-type="table"}).

### 3.2.6. Overall care‐seeking cost {#hpm2905-sec-0020}

When costs from all care‐seeking episodes were combined, the average direct annual costs---KES 53 907 (95% CI, 43 625.4‐64 188.6) (US\$ 528.5 \[95% CI, 427.7‐629.3\])---was higher than the average indirect annual costs---KES 23 174.4 (95% CI, 20 910.0‐25 438.8) (US\$ 227.2 \[95% CI, 205.0‐249.4\])---in the overall sample. Of note, medicine costs in the overall sample, in the diabetes‐only patients, and in the comorbid patients attracted the highest costs. This was closely followed by transport costs in the overall sample and in the comorbid patients while user charges were the second highest cost category after medicines in the diabetes‐only group (Tables [4](#hpm2905-tbl-0004){ref-type="table"}, [5](#hpm2905-tbl-0005){ref-type="table"}, [6](#hpm2905-tbl-0006){ref-type="table"}).

3.3. Impact on household income and coping strategies {#hpm2905-sec-0021}
-----------------------------------------------------

Costs for DM care services was catastrophic to three quarters (n = 123), 75.5% (95% CI, 68.3‐82.1) of patients at the 10% annual household income threshold. Moreover, comorbid patients (n = 94) realized higher catastrophic costs, 79.8% (95% CI, 71.5‐88.1), compared with diabetes‐only patients (n = 69), 69.6% (95% CI, 58.4‐80.7). Alternatively, when transport costs were excluded, (n = 103) 63.2% (95% CI, 55.7‐70.7) of patients incurred catastrophic costs. Among patients experiencing catastrophe, patients in the lowest wealth quintile incurred higher direct costs with few resources to meet the health care costs (Figure [2](#hpm2905-fig-0002){ref-type="fig"}). Nonetheless, Figure [3](#hpm2905-fig-0003){ref-type="fig"} shows a decreasing proportion of patients experiencing catastrophic costs if the 10% annual income threshold was increased. Patients had to borrow (23.3%) from friends/family, sell an asset (29.9%), and use savings (36.8%) to pay for DM care costs.

![Relationship between catastrophic costs and socio‐economic status](HPM-35-290-g002){#hpm2905-fig-0002}

![Percentage experiencing total costs greater than threshold \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](HPM-35-290-g003){#hpm2905-fig-0003}

3.4. Productivity and social impact of diabetes mellitus {#hpm2905-sec-0022}
--------------------------------------------------------

Patients were asked to report any work days missed due to DM illness in the last 3 months before the survey. Of the 163 patients, 33% reported to miss a median of 21 (IQR, 7‐60) working days. Forty‐five percent of the respondents reported disrupted social life due to DM, affecting sexual life (n = 11), job loss (n = 48), divorce (n = 4), and separation from spouse (n = 6).

4. DISCUSSION {#hpm2905-sec-0023}
=============

This study has estimated patient costs for adults with DM that sought care at five public health care facilities in two counties in Kenya. The study\'s main finding is that patient cost for DM are driven by medicine expenses. Similar findings have been reported by recent studies in Kenya and South Africa.[19](#hpm2905-bib-0019){ref-type="ref"}, [34](#hpm2905-bib-0034){ref-type="ref"} Costs due to medicine have been shown to reduce adherence to medication and demand for health services by patients with NCDs.[35](#hpm2905-bib-0035){ref-type="ref"} Past studies conducted in LMICs have however shown that social health insurance schemes do not comprehensively cover the costs for medicines[36](#hpm2905-bib-0036){ref-type="ref"} and that OOP costs, which are majorly contributed by medicines, are a hindrance to attainment of universal health coverage in many low resource settings.[37](#hpm2905-bib-0037){ref-type="ref"}, [38](#hpm2905-bib-0038){ref-type="ref"} Indeed, any reductions or removal of medicine costs is likely to increase access to DM health care services, but additional resources will be required to cover any concomitant increase in service utilization.

The incidence of catastrophic costs documented in this study is arguably high and suggests that DM care in the sampled health facilities is unaffordable to majority of patients, especially those in the lowest wealth quintile whose capacity to pay is limited compared with those in higher socio‐economic group. This is a concern given the high poverty rates in Kenya (36.1%) and that only 19% of Kenya\'s population have a form of health insurance.[39](#hpm2905-bib-0039){ref-type="ref"}, [40](#hpm2905-bib-0040){ref-type="ref"} Furthermore, a past study has shown that families with a member with an NCD incurs three times higher costs compared with families without a member with an NCD.[17](#hpm2905-bib-0017){ref-type="ref"} Our study has also shown that DM patients reporting hypertension comorbidity incur higher costs overall compared with diabetes‐only patients. This places additional financial burden on families of these patients, similar to findings of previous studies.[18](#hpm2905-bib-0018){ref-type="ref"}, [41](#hpm2905-bib-0041){ref-type="ref"}

Our results indicate that transport cost offers an access barrier to DM patients given that it takes a significant proportion of total direct costs in all care‐seeking episodes. In part, the high transport costs reported in this study can be attributed to poor quality of care in public health care facilities. For instance, 48.9% of the patients reported lack of medicines and diagnostic facilities as a reason for not visiting nearest facilities. This phenomenon has been observed from studies in Uganda and Zambia.[42](#hpm2905-bib-0042){ref-type="ref"}, [43](#hpm2905-bib-0043){ref-type="ref"} Prior studies conducted in Kenya highlight that transport costs are a key access barrier especially to poor patients.[38](#hpm2905-bib-0038){ref-type="ref"}, [44](#hpm2905-bib-0044){ref-type="ref"} Moreover, 36% of patients in the overall sample reported a sick visit outside of scheduled clinic appointments incurring an annual mean cost of KES 38 597 (US\$ 378.4). Failure in health‐care delivery has been shown to increase the risk of catastrophe, exacerbate socio‐economic iniquities, and reduce the probability of comprehensive treatment.[45](#hpm2905-bib-0045){ref-type="ref"} These findings therefore reiterate the need for policymakers to develop mechanisms to improve quality of care for diabetic patients in public health facilities since this has serious cost implications on patients. Additionally, since more than three quarters (76.7%) of the patients reported attending their routine scheduled clinics monthly, introducing mechanisms to minimize facility visits, for example, by enhancing and supporting self‐care by patients is likely to reduce transport costs.

The indirect costs due DM care in this study are noteworthy. For instance, of the 163 patients enrolled in the study, 48 (29.5%) had to stop working because of DM and 54 (33%) reported a median loss of 21 working days over the past 90‐day period, which is equal to 1 month\'s wage in the informal sector in Kenya. Similarly, the overall mean indirect costs in all care‐seeking episodes was KES 23 174 (US\$ 227.2) and were primarily contributed by long waiting times at health facilities. It has been shown that long‐waiting times while receiving care reduces demand for chronic care services.[46](#hpm2905-bib-0046){ref-type="ref"} To achieve optimal efficiency and increase demand for service delivery for patients with chronic illnesses like diabetes, there is urgent need to redesign health service delivery for these patients with a view to making care more patient‐centred to meet the unique needs of these patients.

5. LIMITATIONS {#hpm2905-sec-0024}
==============

Our study had some limitations. Due to the recall periods, results may be subject to recall bias. Our study only focused on those who utilized health services, thus excluding those with undiagnosed diabetes who may still incur costs due to symptoms associated with diabetes. Also, costs reported in our study could be potentially overestimated since patients were selected purposefully. Consequently, our findings are not nationally representative. Also, our study relied on the diagnosis reported by patients, hence could not distinguish between type 1 and type 2 diabetes. Use of an official minimum wage to estimate productivity losses for all patients could have potentially overestimated indirect costs among patients who were unemployed prior to their illness or underestimated indirect costs among those who were employed.[30](#hpm2905-bib-0030){ref-type="ref"} These limitations notwithstanding, the findings presented are potentially useful as inputs in costing and/or cost‐effectiveness models that require patient cost and suggest there are significant OOP costs associated with DM management in public facilities in Kenya, which offer a barrier of access to care.
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